Alumis Inc. Common Stock

Day range

$5.78 – $6.53

Open

$6.51

Prev close

$6.55

Volume

922.5K

Market cap

$847.8M

Shares out

129.44M

P/E

—

P/S

114.60

P/B

1.88

P/FCF

—

ROE

-97.1%

ROA

-78.3%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 4, 2026

• Clinical trial resultsSep 1, 2026

  On September 1, 2026, Alumis Inc. issued a press release titled “Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE).” The Company is also filing slides presented by the Company at a webcast regarding the LUMUS Phase 2b topline results on September 1, 2026.

• Clinical trial resultsAug 10, 2026

  Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

• New auditor engagementJul 2, 2026

  The Company's stockholders ratified the appointment by the Company's Audit Committee of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2026. The final voting results are as follows: 105,924,017 votes for, 283,113 votes against, 242,002 abstentions.

• Investor presentationJun 29, 2026

  On June 29, 2026, Alumis Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts, and others. The presentation is available on the Company's website and a copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

• Clinical trial resultsMar 30, 2026

  Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Days to cover

4.9

Short interest

11.08M

Avg volume

2.28M

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
  positiveThe Motley Fool· May 17, 2026
• The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight
  positiveGlobeNewswire Inc.· Apr 14, 2026
• Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
  positiveGlobeNewswire Inc.· Mar 28, 2026
• Alumis Announces Pricing of Upsized Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Jan 7, 2026
• Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
  positiveThe Motley Fool· Jan 6, 2026